To examine the efficacy of prostate-specific antigen (PSA) density (PSAD; serum PSA/prostate volume) as a predictor of clinical outcome of patients undergoing radical retropubic prostatectomy for clinically confined prostate cancer, and its ability to determine the presence of micrometastatic disease.
J. Bentley Squier Urologic Clinic, Columbia-Presbyterian Medical Center, Department of Urology, College of Physicians and Surgeons, Columbia University, New York, New York.
